NeoGenomics will report its fourth quarter and full year 2025 financial results prior to the open of the U.S. financial ...

NeoGenomics is transitioning from a commodity diagnostic provider to a comprehensive precision oncology platform. Read why ...

NeoGenomics (NEO) on Monday said for the fourth quarter of 2025, it expects to report total revenue of approximately $190 million, representing year-over-year growth of 11%. For the full-year 2025, ...

NeoGenomics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.

FT. MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc. (“NeoGenomics” or the “Company”) (NASDAQ: NEO), a leading oncology testing services company, today announced that Tony Zook has officially assumed ...

NeoGenomics is a small-cap provider of cancer genetics diagnostics. They boast one of the most comprehensive oncology-focused testing menus in the world to help physicians diagnose and treat cancer. I ...

NeoGenomics (NASDAQ:NEO) has observed the following analyst ratings within the last quarter: In the last 3 months, 4 analysts have offered 12-month price targets for NeoGenomics. The company has an ...

Management raised full-year 2025 revenue guidance to $747 million-$759 million, reflecting 13%-15% growth. Adjusted EBITDA guidance remains unchanged at $55 million-$58 million. Pathline is projected ...

-Collaboration will leverage NeoGenomics’ large oncology diagnostic laboratory and Massive Bio’s proven-at-scale proprietary artificial intelligence platform to accelerate drug discovery and optimize ...

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, today announced that it will report its fourth quarter and full year 2024 financial ...